Feds accuse AstraZeneca of underpaying 318 female and Hispanic employees
Just a few months after a federal jury awarded $2.4 million in damages to a former AstraZeneca sales manager who alleged retaliation for whistleblowing, the pharma is back in hot water over the way it treats employees — and once again, it’s going to cost the company.
The British pharma has agreed to pay $560,000 in back pay and interest to resolve alleged race- and gender-based pay discrimination affecting 318 female and Hispanic employees.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.